# A Trial of Adjuvant Therapy After Hepatocarcinoma Resection Based on Folate Receptor-positive Circulating Tumor Cells

> **NCT04521491** · NA · UNKNOWN · sponsor: **Eastern Hepatobiliary Surgery Hospital** · enrollment: 184 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** FOLFOX4(infusional fluorouracil [FU], leucovorin [LV], and oxaliplatin [OXA]).

## Key facts

- **NCT ID:** NCT04521491
- **Lead sponsor:** Eastern Hepatobiliary Surgery Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2020-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04521491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04521491, "A Trial of Adjuvant Therapy After Hepatocarcinoma Resection Based on Folate Receptor-positive Circulating Tumor Cells". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04521491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*